The latest trading session saw Intuitive Surgical, Inc. (ISRG) ending at $374.82, denoting a +0.78% adjustment from its last day's close. This change lagged the S&P 500's 1.23% gain on the day. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 1.7%.Shares of the company have appreciated by 11.54% over the course of the past month, outperforming the Medical sector's gain of 3.16% and the S&P 500's gain of 0.94%.Analysts and investors alike will be keeping a close eye on the performance of In ...

Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned +11.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical, Inc. belongs, has gained 3.1% over this period. Now the key question is: Where could the stock be hea ...

Intuitive Surgical Inc. (ISRG, Financial) is an absolute monster of a health care stock. The company has returned over 600% over the past 10 years, easily dwarfing the 160% returns of the S&P 500 Index. Over the same period, the Health Care Select Sector ETF (XLV, Financial) returned 148%. Most of the growth in Intuitive Surgical was seen as hospitals, large medical institutions and integrated delivery networks such as Kaiser Permanente jumped onto the trend of using its robotic surgery systems at their hea ...

Intuitive Surgical, Inc. (ISRG) is well poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by solid 2023 results and its progress on the artificial intelligence (AI) front, is expected to contribute further. Risks pertaining to procedure adoption and stiff competition persist.Shares of this currently Zacks Rank #3 (Hold) company have risen 38.4% in the past year against the industry’s 0.1% decline. The S&P 500 Index has gained 20.6% during the same time frame.I ...

The most recent trading session ended with Intuitive Surgical, Inc. (ISRG) standing at $362.33, reflecting a -0.38% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a downswing of 0.62%, while the tech-heavy Nasdaq depreciated by 0.19%.Coming into today, shares of the company had gained 10.74% in the past month. In that same time, the Medical sector gained 4.61%, while the S&P 500 gained 1.56%.The upcoming earnings release of Intu ...

Intuitive Surgical, Inc. (ISRG) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

Intuitive Surgical, Inc. (ISRG)财报预期 - ISRG本季度每股收益预期为1.48美元，高于Zacks共识预期1.47美元[3] - 分析师最近提高了对ISRG的估算，使得股票的Zacks盈利ESP达到+0.39%[3] ISRG盈利预期修订 - ISRG近期看到有利的盈利预期修订活动[2] - 最近的盈利预期修订表明Intuitive Surgical的前景看好[6] ISRG投资潜力 - 具有Zacks排名3和正面ESP的ISRG可能在盈利季节取得成功[5] - 具有正面盈利ESP和Zacks排名3或更好的股票，有70%的时间会有正面惊喜，平均年回报率超过28%[4]

公司业绩 - Intuitive Surgical (ISRG)股票在2023年表现出色，股价创下历史新高[1] - 公司预计2024年全球达芬奇手术系统的手术数量增长为13%至16%[5] 产品发展 - 公司在不断扩大手术平台，推出了Ion和SP两款新产品，并计划在2024年在新市场如日本增加安装量[6]

公司业绩 - Intuitive Surgical, Inc. (ISRG)属于Zacks Medical - Instruments行业，过去两个季度一直超过盈利预期[1] - 在最近一个季度，公司预计每股盈利为$1.41，实际报告为$1.46，超出预期3.55%[3] - 公司目前的Earnings ESP为+0.39%，分析师对公司的盈利前景持乐观态度[7] - 公司的下一个财报预计将于2024年1月23日发布[7]

初步收入结果 - Intuitive Surgical (ISRG)宣布了2023年第四季度的初步收入结果，预计净销售额至少为19.3亿美元，同比增长17%[3] - 公司销售的仪器和配件达到了11.4亿美元，同比增长22%，主要受到达芬奇手术数量和价格上涨的推动[4] - 2023年，ISRG预计收入为71.2亿美元，同比增长14%[5] 全球达芬奇手术增长 - 公司表示，2023年第四季度全球达芬奇手术增长约21%，系统放置量增长12%[6] - 在2023年第四季度，几乎一半的系统放置是根据运营租赁安排进行的[9] COVID-19影响 - ISRG表示，2023年下半年COVID-19的干扰微乎其微，随着2023年逐渐退出COVID-19，中国手术量恢复，这一趋势可能会延续到接下来的两个季度[10]